The only once-daily oral preventive CGRP receptor antagonist1

Turn on quick and continuous migraine preventive power with QULIPTA

Across a 12-week clinical trial (QULIPTA 60 mg)*:

Month Icon

Significant 54% reduction in mean monthly migraine days vs 33% for placebo1,2

– Similar results were seen in the Phase 2b/3 Dose-finding Study

Reduction Icon

Quick migraine day reductions were observed Day 1 after the first dose, Week 1, and Month 13

Patient Icon

Over 60% of patients cut their migraine days by at least half vs 29% for placebo1

*Data from the Phase 3 ADVANCE trial.

*Data from the Phase 3 ADVANCE trial.